The role of parvalbumin interneuron dysfunction across neurodegenerative dementias
- PMID: 39306248
- DOI: 10.1016/j.arr.2024.102509
The role of parvalbumin interneuron dysfunction across neurodegenerative dementias
Abstract
Parvalbumin-positive (PV+) basket neurons are fast-spiking, non-adapting inhibitory interneurons whose oscillatory activity is essential for regulating cortical excitation/inhibition balance. Their dysfunction results in cortical hyperexcitability and gamma rhythm disruption, which have recently gained substantial traction as contributing factors as well as potential therapeutic targets for the treatment of Alzheimer's Disease (AD). Recent evidence indicates that PV+ cells are also impaired in Frontotemporal Dementia (FTD) and Dementia with Lewy bodies (DLB). However, no attempt has been made to integrate these findings into a coherent pathophysiological framework addressing the contribution of PV+ interneuron dysfunction to the generation of cortical hyperexcitability and gamma rhythm disruption in FTD and DLB. To fill this gap, we epitomized the most recent evidence on PV+ interneuron impairment in AD, FTD, and DLB, focusing on its contribution to the generation of cortical hyperexcitability and gamma oscillatory disruption and their interplay with misfolded protein accumulation, neuronal death, and clinical symptoms' onset. Our work deepens the current understanding concerning the role of PV+ interneuron dysfunction across neurodegenerative dementias, highlighting commonalities and differences among AD, FTD, and DLB, thus paving the way for identifying novel biomarkers and potential therapeutic targets for the treatment of these diseases.
Keywords: Alzheimer’s disease; Cortical hyperexcitability; Dementia with Lewy bodies; Frontotemporal dementia; Gamma rhythm disruption; Parvalbumin-positive interneurons.
Copyright © 2024. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest ES and GK are scientific co-founders and SR is in the scientific advisory board of Sinaptica Therapeutics. ES is a scientific advisor for BottNeuro AG. HH declares no competing financial interests related to the present article. This work was initiated during his academic appointment at Sorbonne University, Paris, France, and reflects his opinion entirely and exclusively. He is an employee of Eisai Inc. The present article has been initiated and prepared as part of his academic position at Sorbonne University, Paris, France, and reflects his opinion entirely and exclusively. He served as Senior Associate Editor and currently as Reviewing Editor for the Journal Alzheimer’s & Dementia.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
